DOJ sues Forest for False Claims Act violations
Pharma Compliance Alert, March 4, 2009
Forest Laboratories allegedly improperly marketed its antidepressants Celexa and Lexapro for unapproved pediatric use and paid kickbacks to induce physicians to prescribe the drugs, according to a Department of Justice (DOJ) release.
The company’s illegal promotional practices surrounding Celexa and Lexapro caused thousands of false and fraudulent claims to be submitted to federal healthcare programs, the DOJ alleged.
Read more about the False Claims Act allegaions against Forest.
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- COT basics to best
- Searched
